Stock Price & Analysis

The S1 support level for CGEM Stock is $8.04 ,The R1 resistant level for CGEM Stock is $9.27.

As of the end of day on 2025-03-06, the price of CGEM Stock was $8.45.

The target price for CGEM Stock according to analyst rating is 32.80, with the highest price target at 36.00 and the lowest at 29.00. Analysts have a Strong Buy rating on CGEM Stock overall.

The market cap of CGEM is $493.3M.

Cullinan Oncology, Inc. is a biopharmaceutical company. The Company is focused on creating standards of care for patients with cancer. The Company’s lead candidate, unpartnered program, CLN-619, is a monoclonal antibody designed to stabilize expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by both cytotoxic innate and adaptive immune cells. The Company is evaluating CLN-978, is a CD19xCD3 T cell engager with extended serum half-life and, based on preclinical data, robust potency against target cells expressing low levels of CD19. The Company's Zipalertinib (CLN-081/TAS6417), is an orally available small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 (EGFRex20) insertion mutations with relative sparing of cells expressing wild-type EGFR. The Company’s other product candidates include CLN-049, CLN-418, and CLN-617.

CGEM has a total of 85 employees.